Oculis Holding Stock Price, News & Analysis

Oculis (NASDAQ: OCS) reported Q2 2025 financial results and provided updates on its ophthalmology pipeline. The company maintained a cash position of $201.3 million as of June 30, 2025, with runway into early 2028, supplemented by a $123.7 million BlackRock loan facility.

Key pipeline developments include: OCS-01's Phase 3 DIAMOND trials completion of enrollment with over 800 patients for diabetic macular edema treatment, with topline results expected Q2 2026; Privosegtor (OCS-05) advancing to Phase 2/3 trial in acute optic neuritis in 1H 2026 following positive Phase 2 results; and Licaminlimab (OCS-02) preparing for genotype-based Phase 2/3 trial in dry eye disease in 2H 2025.

Financial results showed R&D expenses of $18.1 million for Q2 2025, slightly down from Q2 2024, and a year-to-date net loss of $67.9 million, increased from $41.5 million in the same period 2024.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic conditions, announced its participation in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.

Two key presentations are scheduled: CFO Sylvia Cheung will deliver a corporate update available via webcast at 7:00am ET, while R&D President Snehal Shah will participate in a panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00am to 12:00pm ET. Both presentations will be accessible for replay through Oculis' website.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic conditions, announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.

Two key presentations are scheduled: CFO Sylvia Cheung will deliver a corporate update available via webcast at 7:00 AM ET, while R&D President Snehal Shah will participate in a panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00 AM to 12:00 PM ET. Both presentations will be accessible for replay through Oculis' website.

Oculis Holding AG (Nasdaq: OCS) held its 2025 Annual General Meeting on June 4, 2025, where shareholders approved all agenda items. Key approvals included the 2024 Annual Report, which showed a statutory loss of CHF 5.17 million for 2024, and an accumulated balance sheet loss of CHF 46.57 million.

The meeting resulted in the re-election of Anthony Rosenberg as Board Chair and seven other board members. Shareholders approved compensation packages including USD 2.47 million in fixed compensation for executive committee members and a maximum of USD 15.5 million in equity-based compensation. Additionally, shareholders approved a capital band of 27.26 million registered shares and a conditional share capital for employees of up to 12.48 million shares.

Oculis (NASDAQ: OCS) has amended its loan agreement with BlackRock, significantly expanding its borrowing capacity to CHF 75 million, with potential increase to CHF 100 million. The loan comprises three tranches of CHF 25 million each, plus an additional potential CHF 25 million subject to mutual agreement.

The enhanced facility provides financial flexibility beyond current cash reserves as Oculis approaches key milestones, including FDA discussions for Privosegtor in three indications, initiation of Licaminlimab Phase 2/3 trial, and OCS-01 Phase 3 trial results. The company's current cash position extends runway into early 2028.

Oculis (NASDAQ:OCS) announced the vesting and settlement of Restricted Stock Units (RSUs) for its directors, specifically for CEO Riad Sherif. The company has published the required notifications of transactions by persons discharging managerial responsibilities, in compliance with regulatory requirements.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in several upcoming investor conferences in May 2025.

The company's leadership team, including CEO Riad Sherif, MD and CFO Sylvia Cheung, will present at four major conferences: Bio€quity Europe in Bruges, Bank of America Healthcare Conference in Las Vegas, H.C. Wainwright Annual BioConnect at Nasdaq in New York, and Stifel Virtual Ophthalmology Forum. One-on-one meetings with investors will be available during these events.

Webcast links for the presentations will be accessible on the Events & Presentation page of the Oculis website under the Investors & Media section.

Oculis (OCS) has announced the filing of notifications regarding annual equity incentive awards granted to its board directors. The notifications specifically pertain to transactions by T Rosenberg, C Ackermann, A Khanani, and R Warner as part of the June 2025 Board of Directors grant program. These disclosures are standard regulatory filings required for transactions by persons discharging managerial responsibilities within the company.

Oculis Holding AG (Nasdaq: OCS) held its 2025 Annual General Meeting on June 4, where shareholders approved all agenda items. The company reported a loss of CHF 5.18 million for 2024, with an accumulated balance sheet loss of CHF 46.58 million. Anthony Rosenberg was re-elected as Board chairperson, along with seven other board members. Shareholders approved compensation packages including USD 572,000 for non-executive board members' fixed compensation, USD 2.15 million for equity-based compensation, and executive committee compensation including USD 2.48 million fixed compensation and USD 1.75 million variable compensation for 2026. Additionally, a maximum of USD 15.5 million was approved for executive equity-based compensation. The meeting also approved a capital band of 27.27 million registered shares and a conditional share capital for employees of CHF 124,800.